| Sep 26 |
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
|
| Sep 19 |
Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays
|
| Sep 17 |
Theratechnologies Sees Risk of Supply Disruption for Its EGRIFTA SV Drug in Early 2025
|
| Sep 17 |
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
|
| Sep 9 |
Theratechnologies to Present at Upcoming Investor Conferences in September
|
| Aug 26 |
Positive Signs As Multiple Insiders Buy Theratechnologies Stock
|
| Aug 1 |
Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value Investors
|
| Jul 16 |
Theratechnologies Second Quarter 2024 Earnings: Beats Expectations
|
| Jul 16 |
Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock
|
| Jul 10 |
HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars
|
